Log in or Sign up for Free to view tailored content for your specialty!
Cell Therapy News
FDA further delays decision on lisocabtagene maraleucel CAR-T for large B-cell lymphoma
The FDA for a second time delayed a decision on a biologics license application for lisocabtagene maraleucel, a chimeric antigen receptor T-cell therapy for the treatment of adults with relapsed or refractory large B-cell lymphoma.
Letetresgene autoleucel safe, active in advanced synovial sarcoma
Letetresgene autoleucel demonstrated clinical activity among patients with advanced synovial sarcoma, according to final phase 1 study results presented at the virtual Society for Immunotherapy of Cancer Annual Meeting.
Log in or Sign up for Free to view tailored content for your specialty!
Letetresgene autoleucel safe, active in advanced synovial sarcoma
Letetresgene autoleucel demonstrated clinical activity among patients with advanced synovial sarcoma, according to final phase 1 study results presented at the virtual Society for Immunotherapy of Cancer Annual Meeting.
AABB installs 2020-2021 president
David R. Green, MSA, has been installed as president of AABB for the 2020-2021 term.
Clinicians need more education on emerging cancer immunotherapies, survey shows
Nearly half of oncology clinicians reported being unfamiliar with emerging immunotherapies, according to survey results presented at the virtual Society for Immunotherapy of Cancer’s Annual Meeting.
Radiation therapy safe before CAR T-cell infusion for advanced multiple myeloma
Localized radiation therapy appeared safe before treatment with chimeric antigen receptor T cells for relapsed or refractory multiple myeloma, according to study results presented at the virtual ASTRO Annual Meeting.
FDA grants orphan drug designation to natural killer cell therapy for multiple myeloma
The FDA granted orphan drug designation to CellProtect, a modified natural killer cell therapy for the treatment of patients with multiple myeloma, according to the agent’s manufacturer.
FDA clears IND application for CAR-T targeting B-cell-activating factor receptor in ALL
The FDA cleared an investigational new drug application for PMB-101, a chimeric antigen receptor T-cell therapy, for the treatment of refractory or relapsed B-cell acute lymphoblastic leukemia.
COVID-19, manufacturing challenges limit cell and gene therapy progress, FDA official says
Progress in the field of gene and cell therapy continues with rapid development despite the negative impact of COVID-19 on research into novel treatments, according to the director of FDA’s Center for Biologics Evaluation and Research.
Autologous vs. allogeneic CAR-T: Decisions must be made ‘carefully and deliberately’
Allogeneic or “off-the-shelf” chimeric antigen receptor T-cell therapies have moved into early-phase clinical testing with the hope that they will offer many advantages over autologous regimens.